Trial Profile
An Open-Label Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Persistent, Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Roche
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.